Safety and Efficacy of Blinatumomab Combined with Standard Chemotherapy in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia: A Promising Approach"
Adding a Blinatumomab by specific TCell engager targetting CD-19 to standard chemotherapy would be safe and efficacious in these infants? Infants with Lymphoblastic Leukaemia have a poor prognosis, particularly with Histone-lysine N-methyltransferase 2A or KMT2A gene rearrangement in which 6 year event free survival is less than 40%. Abstract from study titled Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukaemia. In the new study of safety and efficacy of blinatumomab, a bispecific T-cell engager molecule targeting CD19, in infants with KMT2A-rearranged ALL. In this phase 2 multinational prospective single group study 30 infants older than 1 year of age with acute Lymphoblastic Leukaemia and a KMT2A gene rearrangement received 1 month of chemotherapy followed by continuous 4-week infusion of Blinatumomab patient still resumes (protocol IB, MARMA, HSCT, or OCTODAD plus maintenance therapy). The primary end point was incidence of clinically relevant toxic effects. A...